GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-08-10 pm EDT
63.14 USD   +1.84%
08/09Few U.S. patients with hepatitis C get timely treatment, CDC says
RE
08/09Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups
RE
08/09Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Gets CHMP Backing for Lenacapavir in Multi-Drug Resistant HIV

06/24/2022 | 06:48am EDT

By Colin Kellaher


Gilead Sciences Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its investigational drug lenacapavir for people with multi-drug-resistant HIV.

The recommendation covers lenacapavir for the treatment of HIV-1 infection, in combination with other antiretrovirals, in adults with multi-drug resistant HIV-1 infection for whom it otherwise isn't possible to construct a suppressive anti-viral regimen, the Foster City, Calif., biopharmaceutical company said.

It expects a final decision from the European Commission, which generally follows the CHMP's advice, later this year.

The U.S. Food and Drug Administration earlier this year rejected Gilead's application seeking approval of lenacapavir due to issues related to the vials in which the drug is stored. Gilead recently said it has identified an alternative vial for lenacapavir.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

06-24-22 0848ET

All news about GILEAD SCIENCES, INC.
08/09Few U.S. patients with hepatitis C get timely treatment, CDC says
RE
08/09Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups
RE
08/09Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobili..
BU
08/08GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
08/08GILEAD SCIENCES, INC. : Report
CO
08/08GILEAD SCIENCES, INC. : SEC Filing 10Q-2
CO
08/05OXFORD UNIVERSITY : Oxford spinout MiroBio acquired by Gilead Sciences for $405m
AQ
08/04UBS Adjusts Gilead Sciences Price Target to $65 From $63, Maintains Neutral Rating
MT
08/04Gilead Sciences to Buy UK Biotech Firm MiroBio for $405 Million
MT
08/04Gilead Sciences to Acquire MiroBio
BU
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 25 156 M - -
Net income 2022 3 912 M - -
Net Debt 2022 16 314 M - -
P/E ratio 2022 19,9x
Yield 2022 4,62%
Capitalization 79 138 M 79 138 M -
EV / Sales 2022 3,79x
EV / Sales 2023 3,76x
Nbr of Employees 14 400
Free-Float 100,0%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 63,14 $
Average target price 70,35 $
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-13.04%77 767
VERTEX PHARMACEUTICALS34.69%76 638
REGENERON PHARMACEUTICALS, INC.1.58%66 513
WUXI APPTEC CO., LTD.-23.13%40 267
BIONTECH SE-37.58%38 205
GENMAB A/S-2.28%23 058